The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Open accessAbstract
NAD+ metabolism is implicated in aging and cancer. However, its role in immune checkpoint regulation and immune evasion remains unclear. Here, we find nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ biogenesis, drives interferon γ (IFNγ)-induced PD-L1 expression in multiple types of tumors and governs tumor immune evasion in a CD8+ T cell-dependent manner. Mechanistically, NAD+ metabolism maintains activity and expression of methylcytosine dioxygenase Tet1 via α-ketoglutarate (α-KG). IFNγ-activated Stat1 facilitates Tet1 binding to Irf1 to regulate Irf1 demethylation, leading to downstream PD-L1 expression on tumors. Importantly, high NAMPT-expressing tumors are more sensitive to anti-PD-L1 treatment and NAD+ augmentation enhances the efficacy of anti-PD-L1 antibody in immunotherapy-resistant tumors. Collectively, these data delineate an NAD+ metabolism-dependent epigenetic mechanism contributing to tumor immune evasion, and NAD+ replenishment combined with PD-(L)1 antibody provides a promising therapeutic strategy for immunotherapy-resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
LinkedOmics: analyzing multi-omics data within and across 32 cancer types
Vasaikar, S. V., Straub, P., Wang, J., & Zhang, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1090 · Cited by 2,312
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
NAD + in aging, metabolism, and neurodegeneration
Verdin, E. (2015) · Science · doi:10.1126/science.aac4854 · Cited by 1,319
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
Influence of Metabolism on Epigenetics and Disease
Kaelin, W. G., & McKnight, S. L. (2013) · Cell · doi:10.1016/j.cell.2013.03.004 · Cited by 920
Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Self-citationPhysiological and pathophysiological roles of NAMPT and NAD metabolism.
Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., & Kiess, W. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.117 · Cited by 708
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
The NAD metabolome — a key determinant of cancer cell biology
Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3340 · Cited by 639
Tumour hypoxia causes DNA hypermethylation by reducing TET activity
Thienpont, B., Steinbacher, J., Zhao, H., D’Anna, F., Kuchnio, A., Ploumakis, A., Ghesquière, B., Van Dyck, L., Boeckx, B., Schoonjans, L., et al. (2016) · Nature · doi:10.1038/nature19081 · Cited by 635
Yang, H., Liu, Y., Bai, F., Zhang, J.-Y., Ma, S.-H., Liu, J., Xu, Z.-D., Zhu, H.-G., Ling, Z.-Q., Ye, D., et al. (2013) · Oncogene · doi:10.1038/onc.2012.67 · Cited by 574
Self-citationMenyhárt, O., Nagy, Á., & Győrffy, B. (2018) · Royal Society Open Science · doi:10.1098/rsos.181006 · Cited by 507
Targeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 469
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
NAD+ metabolism governs the proinflammatory senescence-associated secretome
Nacarelli, T., Lau, L., Fukumoto, T., Zundell, J., Fatkhutdinov, N., Wu, S., Aird, K. M., Iwasaki, O., Kossenkov, A. V., Schultz, D., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0287-4 · Cited by 402
Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor.
Decker, T., Lew, D. J., Mirkovitch, J., & Darnell, J. E. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb08026.x · Cited by 374
Li, W., Zhang, X., Lu, X., You, L., Song, Y., Luo, Z., Zhang, J., Nie, J., Zheng, W., Xu, D., et al. (2017) · Cell Research · doi:10.1038/cr.2017.121 · Cited by 374
What does PD-L1 positive or negative mean?
Ribas, A., & Hu-Lieskovan, S. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161462 · Cited by 335
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 314
MethHC: a database of DNA methylation and gene expression in human cancer
Huang, W.-Y., Hsu, S.-D., Huang, H.-Y., Sun, Y.-M., Chou, C.-H., Weng, S.-L., & Huang, H.-D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1151 · Cited by 296
HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas
Lian, Q., Wang, S., Zhang, G., Wang, D., Luo, G., Tang, J., Chen, L., & Gu, J. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.07.003 · Cited by 288
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling
Frank, D. A., Mahajan, S., & Ritz, J. (1999) · Nature Medicine · doi:10.1038/7445 · Cited by 287
Cai, J., Chen, L., Zhang, Z., Zhang, X., Lu, X., Liu, W., Shi, G., Ge, Y., Gao, P., Yang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318882 · Cited by 284
Self-citationA phosphorylation-acetylation switch regulates STAT1 signaling
Krämer, O. H., Knauer, S. K., Greiner, G., Jandt, E., Reichardt, S., Gührs, K.-H., Stauber, R. H., Böhmer, F. D., & Heinzel, T. (2009) · Genes & Development · doi:10.1101/gad.479209 · Cited by 281
Smith, L. K., Boukhaled, G. M., Condotta, S. A., Mazouz, S., Guthmiller, J. J., Vijay, R., Butler, N. S., Bruneau, J., Shoukry, N. H., Krawczyk, C. M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.006 · Cited by 281
Dang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204
Audrito, V., Serra, S., Brusa, D., Mazzola, F., Arruga, F., Vaisitti, T., Coscia, M., Maffei, R., Rossi, D., Wang, T., et al. (2015) · Blood · doi:10.1182/blood-2014-07-589069 · Cited by 199
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Sun, Z., Fourcade, J., Pagliano, O., Chauvin, J.-M., Sander, C., Kirkwood, J. M., & Zarour, H. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3016 · Cited by 198
Lucena-Cacace, A., Otero-Albiol, D., Jiménez-García, M. P., Muñoz-Galvan, S., & Carnero, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2575 · Cited by 159
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
Galli, U., Travelli, C., Massarotti, A., Fakhfouri, G., Rahimian, R., Tron, G. C., & Genazzani, A. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001049 · Cited by 157
Gujar, A. D., Le, S. B., Mao, D. D., Dadey, D. Y. A., Turski, A., Sasaki, Y., Aum, D. J., Luo, J. R., Dahiya, S. M., Yuan, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610921114 · Cited by 139
Lee, J., Kim, H., Lee, J. E., Shin, S., Oh, S., Kwon, G., Kim, H., Choi, Y. H., White, M. A., Paik, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.024 · Cited by 129
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine
Grolla, A. A., Travelli, C., Genazzani, A. A., & Sethi, J. K. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13505 · Cited by 120
Ito, K., Lee, J., Chrysanthou, S., Zhao, Y., Josephs, K., Sato, H., Teruya-Feldstein, J., Zheng, D., Dawlaty, M. M., & Ito, K. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.094 · Cited by 114
Piacente, F., Caffa, I., Ravera, S., Sociali, G., Passalacqua, M., Vellone, V. G., Becherini, P., Reverberi, D., Monacelli, F., Ballestrero, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3079 · Cited by 113
Liu, J., Jiang, J., Mo, J., Liu, D., Cao, D., Wang, H., He, Y., & Wang, H. (2018) · Hepatology · doi:10.1002/hep.30146 · Cited by 112
Self-citationImmunity drives TET1 regulation in cancer through NF-κB
Collignon, É., Canale, A., Wardi, C. A., Bizet, M., Calonne, E., Dedeurwaerder, S., Garaud, S., Naveaux, C., Barham, W. J., Wilson, A. J., et al. (2018) · Science Advances · doi:10.1126/sciadv.aap7309 · Cited by 99
Ohanna, M., Cerezo, M., Nottet, N., Bille, K., Didier, R., Béranger, G. E., Mograbi, B., Rocchi, S., Yvan‐Charvet, L., Ballotti, R., et al. (2018) · Genes & Development · doi:10.1101/gad.305854.117 · Cited by 97
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 96
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Jiang, X., Hu, C., Ferchen, K., Nie, J., Cui, X., Chen, C., Cheng, L., Zuo, Z., Seibel, W. L., He, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02290-w · Cited by 89
Self-citationα-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis
Atlante, S., Visintin, A., Marini, E., Savoia, M., Dianzani, C., Giorgis, M., Sürün, D., Maione, F., Schnütgen, F., Farsetti, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0802-8 · Cited by 88
Travelli, C., Consonni, F. M., Sangaletti, S., Storto, M., Morlacchi, S., Grolla, A. A., Galli, U., Tron, G. C., Portararo, P., Rimassa, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1544 · Cited by 85
Yang, H., Lee, S.-M., Gao, B., Zhang, J., & Fang, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.527531 · Cited by 78
NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Burgos, E. S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795590101 · Cited by 73
Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0125-3 · Cited by 69
Self-citationChang, J., Zhang, B., Heath, H., Galjart, N., Wang, X., & Milbrandt, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002130107 · Cited by 68
TET-Mediated Sequestration of miR-26 Drives EZH2 Expression and Gastric Carcinogenesis
Deng, M., Zhang, R., He, Z., Qiu, Q., Lu, X., Yin, J., Liu, H., Jia, X., & He, Z. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2964 · Cited by 64
Audrito, V., Managò, A., Vecchia, S. L., Zamporlini, F., Vitale, N., Baroni, G., Cignetto, S., Serra, S., Bologna, C., Stingi, A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx198 · Cited by 63
p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer
Filipczak, P. T., Leng, S., Tellez, C. S., Kieu, C., Grimes, M. J., Thomas, C. L., Walton-Filipczak, S. R., Picchi, M. A., & Belinsky, S. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1234 · Cited by 63
Montecucco, F., Cea, M., Bauer, I., Soncini, D., Caffa, I., Lasigliè, D., Nahimana, A., Uccelli, A., Bruzzone, S., & Nencioni, A. (2013) · Current Drug Targets · doi:10.2174/1389450111314060003 · Cited by 59
Wang, J., Zhang, D., Du, J., Zhou, C., Li, Z., Liu, X., Ouyang, G., & Xiao, W. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx869 · Cited by 43
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia
Takao, S., Chien, W., Madan, V., Lin, D.-C., Ding, L.-W., Sun, Q.-Y., Mayakonda, A., Sudo, M., Xu, L., Chen, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.281 · Cited by 38
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Touat, M., Sourisseau, T., Dorvault, N., Chabanon, R. M., Garrido, M., Morel, D., Krastev, D. B., Bigot, L., Adam, J., Frankum, J. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90277 · Cited by 32
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Self-citationEnergy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Metabolic communication in the tumour–immune microenvironment
Kao, K.-C., Vilbois, S., Tsai, C.-H., & Ho, P.-C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01002-x · Cited by 349
Metadata
- Authors
- Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q., Tang, L., Yang, W., & Wang, H.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 33
- Issue
- 1
- Pages
- 110-127.e5
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W3100272746
- Cited by
- 301
- References
- 74
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.